Artiva Biotherapeutics, Inc.
A clinical-stage biotechnology company in San Diego making off-the-shelf natural killer (NK) cell therapies, its lead candidate AlloNK designed to help antibodies destroy B-cells that drive autoimmune diseases like rheumatoid arthritis and lupus. Founded in 2019 as a spin-out of South Korea's GC Cell, it can produce thousands of doses from a single umbilical cord blood donor—a ready-made therapy that doesn't wait for a patient's own cells.
Bought 8.10M
Bought 1.43M
Granted 1.24M · Sold 62.2K
Granted 202.2K · Sold 8.8K
Granted 224.5K · Sold 7.0K
Granted 220.0K
Granted 113.3K · Sold 3.1K
Granted 102.0K · Sold 7.0K
Granted 77.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +5 co-filersDirector, 10% owner, Director · 9 transactions | — | 34.72M | — | 8.10M | — |
| GC Cell Corp +1 co-filer10% owner · 2 transactions | +289.2% | 6.00M | — | 1.43M | — |
| Aslan FredChief Executive Officer, Director · 8 transactions | +301.6% | 1.54M | 1.24M | — | 62.2K |
| Bush JenniferCOO, CLO, Compliance Officer · 5 transactions | +123.6% | 337.9K | 202.2K | — | 8.8K |
| Horan ChristopherChief Tech Operations Officer · 5 transactions | +266.4% | 293.4K | 224.5K | — | 7.0K |
| Huston Thad AllenChief Financial Officer · 1 transaction | — | 220.0K | 220.0K | — | — |
| Raymon HeatherSVP, Research and Development · 5 transactions | +261.8% | 148.2K | 113.3K | — | 3.1K |
| Banerjee SubhashisChief Medical Officer · 2 transactions | +189.9% | 145.0K | 102.0K | — | 7.0K |
| Krishnamohan NehaChief Financial Officer · 1 transaction | -3.4% | 99.4K | — | — | — |
| Miralles Gines DiegoPresident & Head of R&D · 1 transaction | — | 77.5K | 77.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +9.45M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.